anti-anxiety drug trials...

BIONOMICS has started the phase one human clinical trial of its anti-anxiety drug BNC210.
The trial would be conducted in groups of healthy male volunteers at the Pain and Anaesthesia Research Clinic at the Royal Adelaide Hospital and was expected to be completed by the end of the year.
"The primary objective of this trial is to evaluate the safety, tolerability and pharmacokinetics of BNC210," the company said.
"A secondary objective is the preliminary evaluation of central nervous system effect."
“Now is the age of anxiety.”